Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies.
Capsaicin and other naturally occurring pungent molecules have been used for centuries as topical analgesics and rubefactants to treat a variety of chronically painful conditions. Recently, instillations of high-concentration capsaicin and resiniferatoxin solutions have been found to be useful for the management of persistent bladder pain or overactive bladder. However, only within the last 7 years has it been appreciated that the selective action of these compounds on a subset of sensory nerve fibres is mediated by agonist activity at a ligand-gated ion channel called the transient receptor potential vanilloid receptor 1 (TRPV1). Accordingly, this discovery has fueled intensive research and drug development efforts, mainly in a search for novel analgesic or anti-inflammatory therapies. Two different, but non-mutually exclusive, strategies are being pursued: optimisation of TRPV1 agonist-based therapies, which can functionally inactivate nociceptive nerve fibres, and identification of receptor antagonists, which would prevent nociceptive fibres from being activated by ongoing inflammatory stimuli. Available information on TRPV1 agonists in development and their biological rationale will be summarised in this review.
Bley
Keith R
KR
NeurogesX, Inc., 981F Industrial Road, San Carlos, CA 94070, USA. kbley@neurogesx.com
D002211:Capsaicin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D010146:Pain / Q000188:drug therapy*; D011955:Receptors, Drug / Q000819:agonists* / Q000378:metabolism*; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology
D011955:Receptors, Drug; D002211:Capsaicin